Value of C-telopeptide-cross-linked type I collagen, osteocalcin, bone-specific alkaline phosphatase and procollagen type I N-terminal propeptide in the diagnosis and prognosis of bone metastasis in patients with malignant tumors

Medical Science Monitor

Volumn 17, Issue 11, 2011, Pages 626-633

  Zhao, Hui ^a   Han, Kui Lu ^a   Wang, Zhi Yu ^a   Chen, Yang ^a   Li, Hong Tao ^a   Zeng, Jun Liu ^a   Shen, Zan ^a   Yao, Yang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Bone metastasis; Bone specifc alkaline phosphatase; C telopeptide cross linked type I collagen; Osteocalcin; Procollagen type I N terminal propeptide

Indexed keywords

ALKALINE PHOSPHATASE; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; OSTEOCALCIN; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; UNCLASSIFIED DRUG;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE CANCER; BONE DESTRUCTION; BONE DEVELOPMENT; BONE METASTASIS; BONE PAIN; BONE RADIOGRAPHY; BONE TURNOVER; BREAST CANCER; CANCER LOCALIZATION; CANCER STAGING; CHEMOLUMINESCENCE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE MARKER; ENZYME SPECIFICITY; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MISCIBILITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOLYSIS; PREDICTIVE VALUE; PROGNOSIS; PROSTATE CANCER; RADIOIMMUNOASSAY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURVIVAL TIME; VISUAL ANALOG SCALE;

EID: 80355128186     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/msm.882047     Document Type: Article

References (24)

1. Demers LM, Costa L, Lipton A: Biochemical markers and skeletal metastases. Cancer. 2000; 88(Suppl.12): 2919-26
2. Ebert W, Muley T, Herb KP, Schmidt-Gayk H: Comparison of bone scin-tigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. Anticancer Res, 2004; 24(5B): 3193-201
3. Koizumi M, Takahashi S, Ogata E: Comparison of serum bone resorp-tion markers in the diagnosis of skeletal metastasis. Anticancer Res, 2003; 23(5b): 4095-99
4. Takahashi S: Evaluation of cancer-induced bone diseases by bone metabolic marker. Clin Calcium, 2006; 16(4): 581-90
5. Leeming DJ, Koizumi M, Byrjalsen I et al: The relative use of Eight col-lagenous and noncollagenous markers for diagnosis of skeletal metas-tases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomarkers Prev, 2006; 15(1): 32-38
6. Lipton A, Cook RJ, Major P et al: Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist, 2007; 12(9): 1035-43
7. Soloway MS, Hardeman SW, Hickey D et al: Stratifcation of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer, 1988; 16: 195-202
8. Fontana A, Delmas PD: Markers of bone turnover in bone metastases. Cancer, 2000; 88(Suppl.12): 2952-60
9. Wada S, Fukawa T, Kamiya S: Bone metabolic markers available in daily practice. Clin Calcium, 2009; 19(8): 1075-82
10. Guise TA, Mohammad KS, Clines G et al: Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res, 2006; 12(20 Pt 2): 6213-16s
11. Yuan J, Ossendorf C, Szatkowski JP et al: Osteoblastic and osteolytic human osteosarcomas can be studied with a new xenograft mouse model producing spontaneous metastases. Cancer Invest, 2009; 27(4): 435-42
12. Lee NK, Sowa H, Hinoi E et al: Endocrine regulation of energy metabolism by the skeleton. Cell, 2007; 130: 456-69
13. Lee AJ, Hodges S, Eastell R: Measurement of osteocalcin. Ann Clin Biochem, 2000; 37: 432-46
14. Chang YS, Kim HJ, Chang J: Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer, 2007; 57(3): 373-80
15. Nakayama H, Yano T, Sagara Y et al: Clinical usefulness of urinary CrossLaps as a sensitive marker of bone metabolism. Endocr J, 1997; 44(4): 479-84
16. Coleman R, Brown J, Terpos E et al: Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev, 2008; 34(7): 629-39
17. le Bricon T, Gay-Bellile C, Cottu P et al: Lectin affnity electrophore-sis of serum alkaline phosphatase in metastasized breast cancer. J Clin Lab Anal, 2010; 24(1): 20-24
18. Cloos PAC, Fledelius C, Christgau S et al: Investigation of bone disease using isomerized and racemized fragments of type I collagen. Calcif Tissue Int, 2002; 72: 8-17
19. Koopmans N, de Jong IJ, Breeuwsma A: Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach. J Urol, 2007; 178(3 Pt 1): 849-53
20. Hernandez MV, Guanabens N, Alvarez L et al: Immunocytochemica evidence on the effects of glucocorticoids on type I collagen synthesisin human osteoblastic cells. Calcif Tissue Int, 2004; 74: 284-93
21. Klepzig M, Sauer-Eppel H, Jonas D et al: Value of procollagen type 1 amino-terminal propeptide in patients with renal cell carcinoma. Anticancer Res, 2008; 28(4C): 2443-46
22. Kong QQ, Sun TW, Dou QY et al: Beta-CTX and ICTP act as indicators of skeletal metastasis status in male patients with non-small cell lung cancer. Int J Biol Markers, 2007; 22(3): 214-20
23. Brasso K, Christensen IJ, Johansen JS: Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 inpatients with metastatic prostate carcinoma. Prostate, 2006; 66 (5): 503-13
24. Klepzig M, Jonas D, Oremek GM: Procollagen type 1 amino-termi-nal propeptide: a marker for bone metastases in prostate carcinoma. Anticancer Res, 2009; 29(2): 671-73